#8 B. X.
7-9-02
Watto

ATTORNEY DOCKET NO. 047664-5002

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	Application of:	
	Brita SCHULZE et al.	)
Applic	cation No.: 09/847,538	Group Art Unit: 1617
Filed:	May 3, 2001	Examiner: L. Wells
For:	CATIONIC DIAGNOSTIC, IMAGING AND THERAPEUTIC AGENTS ASSOCIATED WITH ACTIVATED VASCULAR SITES	) ) )
		RECEIVED
		JUL <b>0 3</b> 2002
Assistant Commissioner for Patents Washington, D.C. 20231 Sir:		TECH CENTER 1600/2900
DIL:	·	

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

ATTORNEY DOCKET NO. 047664-5002

Application No.: 09/847,538

Page 2

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP** 

Sally P. Teng

Reg. No. 45,397

Dated: July 1, 2002

Customer No. 09629 MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, NW Washington, D.C. 20004 (202) 739-3000

SUPPLEMENTAL INFORMATION PESCLOSURE STATEMENT				Attorney Docket No. <b>047664-5002</b>	Appli	Application No. 09/847,538				
(Use several sheets if necessary)				Applicants: Brita Schul	Applicants: Brita Schulze et al.					
everal sheets if necessary)  PTO Form 1449			Filing Date: 05/03/01	Group	Group Art Unit: 1617					
*Evaminer	<del>,                                    </del>		U.S. PA	TENT DOCUMENTS		<u>-</u>				
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing	Date		
		5,840,341	11/24/98	Watts et al.	424	499				
		5,230,883	07/27/93	Kornguth et al.	424	9				
						RE	CE	IVED		
							  L 0 3			
						TECH C	-			
	İ <u></u>		FOREIGN 1	PATENT DOCUMENTS	<u>l</u>		<u> </u>			
						Sub	Trans	lation		
	-	Document Number WO 01/17508	Date 09/08/00	Country PCT	Class	Class	Yes	No		
		WO 00/56288	09/28/00	PCT		1				
		WO 98/40052	09/17/98	PCT						
	_	WO 96/09840	04/04/96	PCT						
•		WO 93/18852	09/30/93	PCT						
		OTHER BOOLINE	NTC (I I I	A AL TOUR DATE DATE	4 Posses	E4- \				
	1		<u>.</u>	ing Author, Title, Date, Pert	<del></del>					
	_	Elbaz et al., 1993, International Journal of Pharmaceutics, 96: R1-R6.								
	-	Klang et al., 1999, Journal of Controlled Release, 57: 19-27.								
	_	Sen et al., 1998, Biochemical and Biophysical Research Communications, 247(2): 223-228, Abstract.								
	¢	Takeuchi <i>et al.</i> , 1996, FEBS Letters, 397: 207-209.								
	A	International Search Report for PCT/IB01/01206								
					,	· · · · · · · · · · · · · · · · · · ·				
Examiner:				Date Considered:						
	nitic1 :£	reference considered -	whather or west	citation is in conformance wi	th MDED 600.	draw line 41	rough s	tation		
				of this form with next communication			nougn c	iation		